Tsukuba, Japan

Yuki Karoji

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: Eisai R&d Management Co., Ltd.. Active years: 2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuki Karoji. Retrieved from https://idiyas.com/inventor/yuki-karoji

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Yuki Karoji: Innovator in Pharmaceutical Chemistry

Introduction

Yuki Karoji is a notable inventor based in Tsukuba, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds with therapeutic potential.

Latest Patents

Karoji holds a patent for a monocyclic pyridine derivative. This invention provides a novel compound that exhibits FGFR inhibitory activity or a pharmaceutically acceptable salt thereof. The patent details a compound represented by a specific formula, which includes various structural components that enhance its pharmaceutical efficacy.

Career Highlights

Karoji is associated with Eisai R&D Management Co., Ltd., where he has been instrumental in advancing research and development initiatives. His work focuses on creating innovative solutions for medical challenges, particularly in the realm of cancer treatment.

Collaborations

Karoji collaborates with esteemed colleagues, including Setsuo Funasaka and Toshimi Okada. These partnerships enhance the research environment and foster innovation within the company.

Conclusion

Yuki Karoji's contributions to pharmaceutical chemistry exemplify the impact of innovative thinking in the medical field. His work continues to pave the way for new therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…